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Introduction: Numerous studies have attempted to identify risk factors for mortality and morbidity in 
maintenance hemodialysis patients. In this study we sought to examine the association of the levels of 
serum C-reactive protein (CRP) with value of Ca×PO4 product, in stable hemodialysis patients.
Patients and Methods: Based on the severity of secondary hyperparathyroidism, patients being 
treated with oral active vitamin D3, calcium carbonate/Renagel tablets at various doses. Fasting serum 
25-hydroxy vitamin D and intact serum parathormone and also serum blood urea nitrogen, CRP, calcium, 
phosphorus, alkaline phosphatase was measured.
Results: A total of 41 patients, enrolled to the study.  The mean patients’ age were 46(17.6) years. The value 
of serum CRP of patients was 8.6 (6.6) mg/l (median 6 mg/l). The value of Ca×PO4 product was 50.5(15.5) 
mg2/dl2   (median: 50 mg2/dl2). In this study, a significant inverse association between Ca×PO4 product 
and the age of the patients was seen. A significant positive correlation of logarithm of serum CRP with 
Ca×PO4 product was found.
Conclusion: The result of this study, revealed the need to further attention to hyperphosphatemia in 
hemodialysis patients.
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Implication for health policy/practice/research/medical education:
In a study on 41stable hemodialysis patients, we found a significant positive correlation of serum C-reactive protein with Ca×PO4 product. The 
result of this study, revealed the need to further attention to hyperphosphatemia in hemodialysis patients.
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Introduction
Various investigations have attempted to identify risk factors 
for mortality and morbidity in hemodialysis patients. Most 
have shown important relations among demographic factors 
such as older age, male gender, white race and mortality (1,2). 
Comorbid situations like diabetes, cardiovascular disease and 
nutritional status (e.g., serum albumin, creatinine) have also 
been consistently associated with mortality and morbidity 
(3-5). In fact one of the factors which potentially connect 
to the mortality and morbidity is the control of mineral 
metabolism (6). The mechanisms underlying the increase 
in mortality and morbidity associated with disturbances 
in mineral metabolism remain speculative. Several reports 
have described the ability of serum phosphorus to potently 
stimulate the phenotypic transformation of vascular smooth 
muscle cells into osteoblasts capable of producing a pro-
mineralizing milieu (7,8). In this  state, supersaturatinion 
of extracellular calcium and phosphorus may promote 
the development of medial wall vascular calcification, a 
pathologic process recognized to be associated with increases 
in arterial stiffness, aortic pulse wave velocity, left ventricular 
size, and all-cause mortality in patients on hemodialysis (9). 
Elevated serum phosphorus level is a predictable adjunct of 
end-stage kidney failure in the absence of dietary phosphate 
restriction or supplemental phosphate binders. The results 
of hyperphosphatemia comprise the development and 
progression of secondary hyperparathyroidism and a 
predisposition to metastatic calcification when the product 
of serum calcium and phosphorus (Ca×PO4) is raised. Both 
of these circumstances may contribute to the substantial 
*Corresponding author: Hamid Nasri M.D, Department of Nephrology, 
Shahrekord University of Medical Sciences, Shahrekord, Iran.  
E-mail: hamidnasri@yahoo.com
http://journalrip.com        DOI: 10.12861/jrip.2012.20  
Nasri H
morbidity and mortality found in patients with end-stage 
kidney failure (6). Recently, a strong emphasis has been 
directed on elevated C-reactive protein (CRP) levels as an 
important risk factor for morbidity and mortality too (10-12). 
Furthermore, an association has been noted between elevated 
CRP levels, atherosclerotic plaques and malnutrition (12). 
Ectopic calcifications are defined as a process of inappropriate 
biomineralization occurring in soft tissues. They are typically 
composed of calcium salts. In hemodialysis patients such a 
condition referred to as metastatic calcification, which is said 
to be responsible for progressive cardiac and vascular injury, 
leading to invalidating clinical complications and increased 
mortality risk (13). Considering that the amount of coronary 
calcium is a marker of atherosclerosis (14), while atherosclerosis 
is at present viewed as an inflammatory disease (15) and while, 
CRP is a marker of cardiovascular risk both in non-uremic (16) 
and uremic subjects (17) that hyperphosphatemia and elevated 
calcium–phosphate product are associated with an increased 
risk of death (6).
Objectives
This study was aimed to elucidate whether and how in end-
stage kidney failure patients on hemodialysis the levels of CRP 
correlate with Ca×PO4 product.
Patients and Methods 
Patients
This cross-sectional study was conducted on patients with 
end-stage kidney failure patients who were undergoing 
regular hemodialysis. According to the intensity of secondary 
hyperparathyroidism, each patient being treated for secondary 
hyperparathyroidism was given oral active vitamin D3 
(Calcitriol; Rocaltrol) (Roche Hexagon; Roche Laboratories 
Inc, New Jersey, USA ), calcium carbonate tablets and Renagel 
(sevelamer; Genzyme Europe B.V.; United Kingdom/Ireland) 
tablet at various doses. According to the severity of anemia, 
patients were prescribed intravenous iron therapy with 
iron Sucrose (Venofer; Vifor (international) Inc. St. Gallen/
Switzerland) at various doses after each dialysis session. All 
patients received treatments of 5 mg folic acid daily, oral 
vitamin B-complex tablets daily, and 2,000 U intravenous 
Eprex (recombinant human erythropoietin [Rhuepo] (Janssen-
Cilag; CILAG-AG  International 6300 Zug/Switzerland) after 
each dialysis session. Exclusion criteria were active or chronic 
infection and using drugs had adverse effects on bone marrow. 
Laboratory tests
Complete blood counts were measured using Sysmex-KX-21N 
cell counter (SYSMEX CORPORATION; Mundelein, Illinois, 
Sysmex America, Inc.). Serum 25-hydroxy (25-OH) Vitamin 
D level (normal range of values is   25 to 125 nmol/L) and 
intact serum PTH (iPTH)   were measured as follows. Blood 
samples were obtained   after an overnight fast, blood sample 
were centrifuged within 15 min of venipuncture, and were 
measured by enzyme-linked immunosorbent assay (ELISA) 
method using DRG kits of Germany. Intact serum PTH (iPTH) 
was measured by the radioimmunoassay (RIA) method using 
DSL-8000 kits of USA (normal range of values is 10-65 pg/
ml). Also peripheral venous blood samples were collected 
after an overnight fast, for biochemical analysis including 
serum post and predialysis blood urea nitrogen (BUN), serum 
C-reactive protein (CRP), albumin (Alb), serum calcium (Ca), 
phosphorus (P)  and  alkaline phosphatase (ALP) and also 
serum ferritin  (by radio immune assay method; RIA)  were 
measured using standard methods.  Body mass index (BMI) 
calculated using the standard formula (post-dialyzed weight 
in kilograms/height in square meters; kg/m2). Duration and 
dosages of hemodialysis treatment were calculated from the 
patients’ records. The duration of each hemodialysis session 
was 4 hours. For statistical analysis, the data are expressed 
as the mean ± standard deviation (SD) and median values. 
Comparison between the groups was done using Student’s 
t-test. Statistical correlations were assessed using partial 
correlation test. CRP was Ln-transformed in all statistical 
analyses because of positive skewness.
Ethical issues
1) The research followed the tenets of the Declaration of 
Helsinki; 2) informed consent was obtained; 3) the research 
was approved by the institutional review board.
Statistical analysis
All statistical analyses were performed using SPSS 11.5 (SPSS 
Inc., Chicago, IL). Statistical significance was determined at a 
P value <0.05.
Results
There was a total of 41 patients (15 women, 26 men), consisting 
of 29 non-diabetic hemodialysis patients and 12 diabetic 
hemodialysis patients. Table 1 illustrated the patients’ mean 
(SD) age, the length of time they were on hemodialysis, the 
dialysis dosage, and the results of laboratory tests. The mean 
patient age was 46 (17.6) years. The value of serum CRP of 
patients was s8.6 mg/l (6.6) (median 6 mg/l). The value of 
Ca×PO4 product was 50.5 (15.5) mg2/dl2   (median: 50 mg2/
dl2).  In this study no significant difference of Ca×PO4 product 
between male or females and diabetics or non-diabetics was 
seen (P >0.05). While a significant difference of serum CRP 
between diabetic and non-diabetics was found (P= 0.014), no 
significant difference of serum CRP between male or female 
groups was seen (P >0.05) .No significant relationship between 
Ca×PO4 product and duration and doses of dialysis was found 
In this study a significant inverse correlation between Ca×PO4 
product and the age of the patients (r= -0.34, P= 0.034) 
(adjusted for duration and doses of dialysis) was detected. 
Also, a significant positive correlation between logarithm of 
serum CRP with age (r= 0.42, P= 0.011) (adjusted for duration 
and doses of dialysis and serum P, iPTH and also ferritin) was 
found. A significant positive correlation of logarithm of serum 
CRP with Ca×PO4 product(r= -0.33, P= 0.047) (adjusted for 
age, duration and doses of dialysis and) was found.
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Discussion
In the present study we found a significant inverse correlation 
between Ca×PO4 product and the ages of the patients and a 
significant positive correlation between of serum CRP with age. 
Furthermore significant positive  correlation of  serum CRP 
with  Ca×PO4 product was  found too. In a study conducted by 
Block et al. found that serum phosphate levels >6.5 mg/dl and 
a calcium–phosphate ion product >72 mg2/dl2 are associated 
with an 18–39% higher risk of death, compared with normal 
reference groups (namely a serum phosphate of 4.4–5.5 mg/
dl and calcium–phosphate product of 43–52 mg2/dl2) (6). 
Block et al. for determining associations among disorders of 
mineral metabolism, mortality, and morbidity in hemodialysis 
patients, data on 40,538 hemodialysis patients with at least one 
determination of serum phosphorus and calcium during the 
last 3 mo of 1997 were analyzed. When examined collectively, 
the population attributable risk percentage for disorders of 
mineral metabolism was 17.5%, owing largely to the high 
prevalence of hyperphosphatemia. Hyperphosphatemia and 
hyperparathyroidism were significantly associated with all-
cause, cardiovascular, and fracture-related hospitalization. 
They concluded that disorders of mineral metabolism are 
independently correlated with mortality and morbidity 
associated with cardiovascular disease and fracture in patients 
on hemodialysis (18). Marco et al. studied on one hundred and 
forty-three hemodialysis patients which were followed for six 
years. They showed an increased risk of cardiovascular death in 
patients with serum P >6.5 mg/dl, PTH >50 pmol/l , Ca×P>52 
(19). High levels of CRP , in renal failure patients , have been 
shown, and high CRP levels in dialysis patients are predictive 
of future cardiovascular events (20-25). Inflammation might 
be a trigger for calcium deposition in the arteries of dialysis 
patients, peculiarly at the end of each dialysis session when 
back-filtration might occur, plasma calcium concentrations 
reach their maximum levels and the patients become alkalotic. 
In this situation it should also be considered that CRP, being a 
member of the pentraxin family, binds to damaged tissue in a 
calcium-dependent manner and shows membrane association 
with multiple calcium ions (26) Moreover, CRP binds to 
enzymatically degraded LDL particles in early atherosclerotic 
lesions, inducing complement activation and promoting the 
development and progression of the atherosclerotic lesion 
(27). The increase of CRP in stable dialysis patients may 
be due to the stimulation of monocytes/macrophages by 
dialysate contaminants and, in turn, may promote by itself 
atherosclerotic changes in the cardiovascular tree. Concomitant 
to such an inflammatory state other cofactors are at work: a high 
oral intake of calcium salts and an excessive vitamin D therapy 
in a daily fashion and a positive calcium balance due to supra-
normal calcium in the dialysate in an intermittent fashion. In 
this case metabolic alkalosis may have an additional role in 
calcium precipitation (26,27). Our study detect an inverse 
association of dialysis adequacy with both serum CRP and 
Ca×PO4 product, indicates that an adequate hemodialysis on 
one hand  will be associated with lower Ca×PO4 product and 
on the other hand diminishes  the  inflammatory state of uremia 
(28,29). We could find a positive correlation between Ca×PO4 
product and serum CRP level. To detect the clinical importance 
of this association, Movilli et al. conducted a study on 47 uremic 
patients (age 65) on regular hemodialysis. Their patients had 
no clinical evidence of either acute infectious or inflammatory 
diseases for at least 4 weeks before the study. They were on 
regular bicarbonate hemodialysis for 6-329 months (median 
42). A significant hyperbolic correlation between Ca×PO4 
and CRP was observed. A piecewise linear regression model 
Table 1. Data of the patients.
Total patients
n=41
Minimum Maximum Mean±SD Median
Age  ( years) 16 80 46 ±17.6 46
DH*  (months) 2 156 29.5±35 29.5
Dialysis amount (Sessions) 18 1584 269±375 153
URR (%) 39 76 58.7±8.75 58
CRP   (mg/l) 3 40 8.6±6.6 6
Hgb  (g/dl) 5 13 9±2 9
25-hydroxy D (nmol/l) 0.3 36 7.6±9.5 3.2
iPTH (Pg/ml) 16 1980 408±440 250
Alb (g/dl) 2.4 5 3.85±0.53 4
Ferritin ( ng/dl) 35 1250 497±287 420
Ca(mg/dl) 5 10 7.7±0.99 8
P(mg/dl) 3 10 6.3±1.9 6.4
Alp (IU/l) 150 5487 632±878 428
Ca×PO4 (mg2/dl2  ) 21 80 50.5±15.5 50
BMI (kg/m2) 16 34 21.4±4.3 20
*Duration of hemodialysis
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analysis identified a break-point for Ca×PO4 at 55 mg2/dl2. They 
showed  that in chronic hemodialysis patients in steady clinical 
conditions with no clinical evidence of either infectious or 
inflammatory diseases, a high Ca×PO4 is associated with high 
CRP concentrations and intensive lowering of Ca×PO4, reduces 
CRP (30). In this view, inflammation might be a trigger for 
calcium deposition in the arteries of dialysis patients, peculiarly 
at the end of each dialysis session when back-filtration might 
occur, plasma calcium concentrations reach their maximum 
levels and the patients become alkalotic (28-30). Therefore an 
elevated Ca×PO4 product and C-reactive protein have been 
associated with coronary artery calcification and increased 
cardiovascular mortality in hemodialysis patients. In fact, the 
view of the clinical problems associated with secondary renal 
hyperparathyroidism in end-stage kidney failure patients has 
changed considerably in the last few years.  While it formerly was 
considered primarily a skeletal disorder, recent data show strong 
associations between renal secondary hyperparathyroidism and 
both disturbed bone/mineral metabolism and the development 
of cardiovascular calcifications, leading to cardiovascular 
morbidity and patient mortality (6,18,31-33). Our findings 
showed the need to further attention to hyperphosphatemia and 
uncontrolled secondary hyperparathyroidism in maintenance 
hemodialysis patients.
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